Drugs / ABT-510
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00586092 | Sep 2005 → Feb 2013 | cancer | Herbert Hurwitz | Completed | No outcome recorded |
| Phase 1 | NCT00584883 | Aug 2003 → Jul 2008 | brain neoplasm | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00113334 | Apr 2005 → Mar 2008 | head and neck cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 25 trials · 1 missed | ||||||
| Phase 2 | NCT00602199 | Nov 2004 → Jun 2005 | cutaneous melanoma | Mayo Clinic | Completed | Missed primary |
| Phase 2 | NCT00061659 | May 2003 → Apr 2006 | soft tissue sarcoma | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00073125 | May 2003 → ? | renal cell carcinoma | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00061672 | Apr 2003 → ? | Hodgkins lymphoma, non-Hodgkin lymphoma | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00061646 | Mar 2003 → ? | non-small cell lung carcinoma | Abbott | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00586092 ↗ |
| Action | Inhibit | “is a potent inhibitor of angiogenesis.” NCT00584883 ↗ |
| Modality | Peptide | “ABT 510 (TSP-1 mimetic peptide)” NCT00584883 ↗ |
| Route | Subcutaneous | “100 mg subcutaneously twice daily” NCT00113334 ↗ |